Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Nonclinical Efficacy, Pharmacokinetic/Pharmacodynamic (PK/PD), and Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Sunday, December 3, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the nonclinical efficacy, pharmacokinetics, and toxicology profile of ALG-055009, a new thyroid hormone receptor beta agonist. This compound shows promise as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight its potential benefits in managing this condition.
Price reaction · baseline $17.5275 (2023-12-01 close) · 5 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a novel thyroid hormone receptor beta agonist.
  • Potential treatment for metabolic dysfunction-associated steatohepatitis (MASH).
  • Promising pharmacokinetic and pharmacodynamic profiles.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-055009?

ALG-055009 is a novel thyroid hormone receptor beta agonist.

What condition does ALG-055009 target?

It targets metabolic dysfunction-associated steatohepatitis (MASH).

What are the key profiles of ALG-055009?

The key profiles include nonclinical efficacy, pharmacokinetics, and toxicology.

Is ALG-055009 safe for patients?

The article discusses its pharmacokinetic and toxicology profiles, indicating potential safety.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-055009 thyroid hormone receptor MASH pharmacokinetics toxicology
Last updated: Dec 3, 2023

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →